Pulmonary Hypertension Clinical Trials
As a patient at Cedars-Sinai, you will have access to the latest clinical trials and research for pulmonary hypertension. Backed by a respected team of specialists and researchers, our clinical trials aim to further the advancement of diagnosing and treating your condition.
Questions? See the Clinical Trials FAQs.
Idiopathic, heritable, connective tissue disease-associated and HIV-associated pulmonary arterial hypertension
Key Inclusion Criteria:
- Confirmed clinical diagnosis of IPAH, HPAH, PAH-CTD, PAH-HIV
- NYHA Functional Class: II or III
- 18-75 years old
This study focuses on patients with pulmonary arterial hypertension (PAH) from the following subgroups: idiopathic PAH (IPAH), heritable PAH (HPAH), PAH associated with connective tissue disease (PAH-CTD) and PAH associated with HIV (PAH-HIV). The study is designed to evaluate the investigational use of a biologic product called CAP-1002. CAP-1002 consists largely of heart stem cells ("CDCs") grown from donated tissue from human heart muscle. The purpose of the study is to determine the maximum feasible dose and safety of CAP-1002 administered by central intravenous infusion (IV line) in PAH patients belonging to one of the subgroups listed above who have been started on PAH-specific medications. CAP-1002 will be used in addition to the participant’s regular treatment regimen.